A phase II study of arsenic trioxide in patients with relapsed or refractory malignant lymphoma
- 145 Downloads
Limited data have been reported regarding the use of arsenic trioxide (ATO) in the treatment of patients with relapsed or refractory malignant lymphoma; therefore, the present phase II study evaluated the efficacy and toxicity of ATO in such patients. A total of 35 patients were treated with ATO (0.25 mg/kg) infused for 1 h daily, 5 days a week, for a 6-week cycle. Patients were evaluated for the efficacy and toxicity of this regimen. The primary outcome evaluated was the overall response rate (ORR), including the complete and partial response rates. The secondary outcomes evaluated were the overall survival (OS), progression-free survival (PFS), and toxicity. Tumor response data were obtained from all 35 enrolled patients. The ORR was 43 %, including complete responses in four patients (11 %) and partial responses in 11 patients (31 %). The median duration of response was 16 weeks (range 11–23 weeks). The median OS was 79 weeks (range 14–171 weeks), and the median PFS was 55 weeks (range 14–135 weeks). Grade I or II hematological toxicities were the most commonly reported adverse events. The results of this study appear promising for the treatment of relapsed or refractory malignant lymphoma, with well-tolerated ATO toxicity.
KeywordsArsenic trioxide Lymphoma Non-Hodgkin lymphoma Hodgkin lymphoma
This study was funded by Heilongjiang Province Science Foundation for Youths (Grant No.QC2012C106).
Conflict of interest
The authors declare that they have no competing interests.
- 4.Huang BT, Zeng QC, Gurung A, Zhao WH, Xiao Z, Li BS. The early addition of arsenic trioxide versus high-dose arabinoside is more effective and safe as consolidation chemotherapy for risk-tailored patients with acute promyelocytic leukemia: multicenter experience. Med Oncol. 2012;29(3):2088–94.CrossRefPubMedGoogle Scholar
- 13.Berenson JR, Boccia R, Siegel D, et al. Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study. Br J Haematol. 2006;135(2):174–83.CrossRefPubMedGoogle Scholar
- 34.Nie L, Zhang Y, Zhang JJ, Wang SZ. Combinational effects of bcl-2 antisense oligodeoxynucleotides with arsenic trioxide on malignant lymphoma cell lines. China Oncol. 2002;12(3):197–200.Google Scholar
- 35.Nie L. Apoptosis induced in malignant lymphoma cells by arsenic trioxide. Ji Nan University, Master’s Thesis. 2000; 1–42.Google Scholar